Atlas Trials

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

Clinical trial NCT07722767 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07722767
Sponsor
Cullinan Therapeutics Inc.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
AML (Acute Myeloid Leukemia)
Start date
2026-10-15
Primary completion
2027-09-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.